Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,624 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01949545 | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment | completed | Phase 1 | 46 | AmgenINDUSTRY | 4 | May 2, 2017 | clinicaltrials |
| NCT01471210 | Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 124 | Bristol-Myers SquibbINDUSTRY | 4 | Apr 19, 2017 |
| clinicaltrials |
| NCT01359696 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 2 | Apr 12, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT00934856 | A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 98 | Hoffmann-La RocheINDUSTRY | 4 | Apr 6, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT02174887 | Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer(MOAnab1) | completed | Phase 1 | 19 | Institut Paoli-CalmettesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | terminated | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 4 | Mar 13, 2017 | clinicaltrials |
| NCT01389427 | Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).(T³) | completed | Phase 1 / Phase 2 | 41 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT02640365 | A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer(DOUBLIRI) | completed | Phase 1 | 10 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT00251888 | CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto | completed | Phase 1 | 15 | ARCAGY/ GINECO GROUPOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT01188252 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies | completed | Phase 1 | 112 | BayerINDUSTRY | 3 | Jan 9, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT01915576 | Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients | completed | Phase 1 | 79 | BayerINDUSTRY | 4 | Dec 28, 2016 | clinicaltrials |
| NCT02880943 | Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)(EIFFEL) | unknown | Phase 1 / Phase 2 | 42 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Nov 8, 2016 | clinicaltrials |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma(GAUDI) | completed | Phase 1 | 137 | Hoffmann-La RocheINDUSTRY | 6 | Nov 4, 2016 | clinicaltrials |
| NCT00559533 | A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors | completed | Phase 1 | 106 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00721266 | A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors. | completed | Phase 1 | 102 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00773526 | A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors. | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00854126 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Genentech, Inc.INDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00930514 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | completed | Phase 1 | 281 | Hoffmann-La RocheINDUSTRY | 22 | Nov 2, 2016 | clinicaltrials |
| NCT01143740 | A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery | completed | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01308684 | A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma | completed | Phase 1 | 22 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01358903 | A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors | completed | Phase 1 | 65 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01462175 | A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia | completed | Phase 1 | 99 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01513083 | A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function | completed | Phase 1 | 28 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01605526 | A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma | completed | Phase 1 | 23 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01635296 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 43 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01641250 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 44 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01894256 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 5 | Oct 13, 2016 | clinicaltrials |
| NCT00517530 | A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Oct 11, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT01046266 | A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 62 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2016 | clinicaltrials |
| NCT01447225 | Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors | completed | Phase 1 | 43 | Merrimack PharmaceuticalsINDUSTRY | 2 | Sep 14, 2016 | clinicaltrials |
| NCT02897986 | Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors(PROVIN) | unknown | Phase 1 | 54 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00287846 | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | completed | Phase 1 / Phase 2 | 40 | UNICANCEROTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02870010 | Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres(IDASPHERE) | completed | Phase 1 | 21 | Centre Hospitalier Universitaire DijonOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT01132664 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | terminated | Phase 1 / Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 6 | Aug 17, 2016 | clinicaltrials |
| NCT02862288 | Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.(TherMO) | completed | Phase 1 / Phase 2 | 30 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT02861222 | Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma(MYOCET) | completed | Phase 1 | 13 | Central Hospital, Nancy, FranceOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01082887 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) | terminated | Phase 1 / Phase 2 | 18 | Nantes University HospitalOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Merrimack PharmaceuticalsINDUSTRY | 2 | Aug 4, 2016 | clinicaltrials |
| NCT01511536 | Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | SanofiINDUSTRY | 3 | Jul 28, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials